Advertisement

Submit Manuscripts
Author Information
Subscribe/Renew
Order Reprints
Email Alerts
Feedback
RSS Feed
CME

About the Journal
Editorial Board & Staff

JACC Imaging Homepage JACC Interventions Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?
Click here
to sign up now!

ACC.org
Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions

Click here for more guidelines.
ACCF/ASNC/ACR/
AHA/ASE/SCCT/
SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging
SCIENCE ADVISORY: Percutaneous Device Closure of Patent Foramen Ovale for Secondary Stroke Prevention
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 49:1733-1739, doi:10.1016/j.jacc.2006.10.081 (Published online 30 March 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2006.10.081v1
49/16/1733    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (97)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jourdain, P.
Right arrow Articles by Juillière, Y.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jourdain, P.
Right arrow Articles by Juillière, Y.

EXPEDITED REVIEW

Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure

The STARS-BNP Multicenter Study

Patrick Jourdain, MD*,{dagger},{ddagger},*, Guillaume Jondeau, MD, PhD§, François Funck, MD{ddagger}, Pascal Gueffet, MD||, Alain Le Helloco, MD, Erwan Donal, MD, Jean F. Aupetit, MD#, Marie C. Aumont, MD§, Michel Galinier, MD, PhD**, Jean C. Eicher, MD{dagger}{dagger}, Alain Cohen-Solal, MD, PhD{ddagger}{ddagger} and Yves Juillière, MD, PhD§§

* René Descartes University, Paris, France
{dagger} Georges Pompidou Hospital, Paris, France
§ Department of Cardiology, Bichat University Hospital, Paris, France
{ddagger}{ddagger} Department of Cardiology, Centre Hospitalier Universitaire de Lariboisière, Paris, France
{ddagger} Hospitalier de Rene Dubos, Pontoise, France
|| Centre Hospitalier Universitaire de Nantes, Nantes, France
Centre Hospitalier Universitaire de Rennes, Rennes, France
# Hopital Saint Luc Lyon, Lyon, France
** Department of Cardiology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
{dagger}{dagger} Centre Hospitalier Universitaire de Dijon, Dijon, France
§§ Department of Cardiology, Centre Hospitalier Universitaire de Vandoeuvre Les Nancy, Vandoeuvre Les Nancy, France.

Manuscript received September 12, 2006; revised manuscript received October 10, 2006, accepted October 22, 2006.

* Reprint requests and correspondence: Dr. Patrick Jourdain, Hopital de Pontoise, CH Rene Dubos, Heart Failure Department, 6 Avenue de France, Pontoise, 95301 France. (Email: patrick.jourdain{at}ch-pontoise.fr).

Objectives: The aim of this multicenter study was to evaluate the prognostic impact of a therapeutic strategy using plasma brain natriuretic peptide (BNP) levels.

Background: The prognosis of chronic heart failure (CHF) remains poor, even among patients treated in specialized departments.

Methods: A total of 220 New York Heart Association functional class II to III patients considered optimally treated with angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, and diuretics by CHF specialists were randomized to medical treatment according to either current guidelines (clinical group) or a goal of decreasing BNP plasma levels <100 pg/ml (BNP group). Outpatient visits were scheduled every month for 3 months, then every 3 months. The primary combined end point was CHF-related death or hospital stay for CHF.

Results: Both groups were similar for baseline clinical and biological characteristics. Left ventricular ejection fraction was slightly lower in the BNP group than in the clinical group (29.9 ± 7.7% vs. 31.8 ± 8.4%, p = 0.05). At the end of the first 3 months, all types of drugs were changed more frequently in the BNP group. Mean dosages of ACEIs and beta-blockers were significantly higher in the BNP group (p < 0.05), whereas the mean increase in furosemide dosage was similar in both groups. During follow-up (median 15 months), significantly fewer patients reached the combined end point in the BNP group (24% vs. 52%, p < 0.001).

Conclusions: In optimally treated CHF patients, a BNP-guided strategy reduced the risk of CHF-related death or hospital stay for CHF. The result was mainly obtained through an increase in ACEI and beta-blocker dosages.

Abbreviations and Acronyms
  ACEI = angiotensin-converting enzyme inhibitor
  ARB = angiotensin II-receptor blockers
  BNP = brain natriuretic peptide
  CHF = chronic heart failure
  LVEF = left ventricular ejection fraction
  NYHA = New York Heart Association




This article has been cited by other articles:


Home page
 Eur Heart JHome page
J. E.A. Blair, S. Khan, M. A. Konstam, K. Swedberg, F. Zannad, J. C. Burnett Jr, L. Grinfeld, A. P. Maggioni, J. E. Udelson, C. A. Zimmer, et al.
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial
Eur. Heart J., July 1, 2009; 30(13): 1666 - 1673.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Cohen-Solal, D. Logeart, B. Huang, D. Cai, M. S. Nieminen, and A. Mebazaa
Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure
J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2343 - 2348.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Gheorghiade and P. S. Pang
Are BNP Changes During Hospitalization for Heart Failure a Reliable Surrogate for Predicting the Effects of Therapies on Post-Discharge Mortality?
J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2349 - 2352.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J. G.F. Cleland, A. P. Coletta, A. L. Clark, and D. Cullington
Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA
Eur J Heart Fail, June 1, 2009; 11(6): 622 - 630.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
L Lorgis, M Zeller, G Dentan, P Sicard, P Buffet, I L'Huillier, J C Beer, M Vincent-Martin, H Makki, P Gambert, et al.
Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study
BMJ, May 6, 2009; 338(may06_1): b1605 - b1605.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. Frankenstein, A. Remppis, J. Frankenstein, G. Hess, D. Zdunek, K. Slottje, H. A. Katus, and C. Zugck
Variability of N-Terminal Probrain Natriuretic Peptide in Stable Chronic Heart Failure and Its Relation to Changes in Clinical Variables
Clin. Chem., May 1, 2009; 55(5): 923 - 929.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. Vassalle and M. G. Andreassi
Genetic Polymorphisms of the Natriuretic Peptide System in the Pathogenesis of Cardiovascular Disease: What Lies on the Horizon?
Clin. Chem., May 1, 2009; 55(5): 878 - 887.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. A. Hlatky and P. A. Heidenreich
The Year in Epidemiology, Health Services Research, and Outcomes Research
J. Am. Coll. Cardiol., April 21, 2009; 53(16): 1459 - 1466.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
M. Kubanek, K. M. Goode, V. Lanska, A. L. Clark, and J. G.F. Cleland
The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction
Eur J Heart Fail, April 1, 2009; 11(4): 367 - 377.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Gheorghiade and P. S. Pang
Acute heart failure syndromes.
J. Am. Coll. Cardiol., February 17, 2009; 53(7): 557 - 573.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll Cardiol ImgHome page
R. W. Troughton and A. M. Richards
B-type natriuretic peptides and echocardiographic measures of cardiac structure and function.
J. Am. Coll. Cardiol. Img., February 1, 2009; 2(2): 216 - 225.
[Abstract] [Full Text] [PDF]

Home page
 Fam PractHome page
J. C Kelder, F. H Rutten, and A. W Hoes
Clinically relevant diagnostic research in primary care: the example of B-type natriuretic peptides in the detection of heart failure
Fam. Pract., February 1, 2009; 26(1): 69 - 74.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. Pfisterer, P. Buser, H. Rickli, M. Gutmann, P. Erne, P. Rickenbacher, A. Vuillomenet, U. Jeker, P. Dubach, H. Beer, et al.
BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial
JAMA, January 28, 2009; 301(4): 383 - 392.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
I. L. Pina and C. O'Connor
BNP-Guided Therapy for Heart Failure
JAMA, January 28, 2009; 301(4): 432 - 434.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
D. Logeart, J.-P. Gueffet, F. Rouzet, F. Pousset, C. Chavelas, A. C. Solal, and G. Jondeau
Heart rate per se impacts cardiac function in patients with systolic heart failure and pacing: a pilot study
Eur J Heart Fail, January 1, 2009; 11(1): 53 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. Mueller, B. Dieplinger, W. Poelz, G. Endler, O. F. Wagner, and M. Haltmayer
Amino-Terminal Pro-B-Type Natriuretic Peptide as Predictor of Mortality in Patients with Symptomatic Peripheral Arterial Disease: 5-Year Follow-Up Data from the Linz Peripheral Arterial Disease Study
Clin. Chem., January 1, 2009; 55(1): 68 - 77.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. L. Miller, K. A. Hartman, D. E. Grill, J. C. Burnett Jr, and A. S. Jaffe
Only Large Reductions in Concentrations of Natriuretic Peptides (BNP and NT-proBNP) Are Associated with Improved Outcome in Ambulatory Patients with Chronic Heart Failure
Clin. Chem., January 1, 2009; 55(1): 78 - 84.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. P. Coletta, D. Cullington, A. L. Clark, and J. G.F. Cleland
Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF
Eur J Heart Fail, December 1, 2008; 10(12): 1264 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L. Frankenstein, A. Remppis, M. Nelles, B. Schaelling, D. Schellberg, H. Katus, and C. Zugck
Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status
Eur. Heart J., November 1, 2008; 29(21): 2634 - 2640.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
P. Ray, S. Delerme, P. Jourdain, and C. Chenevier-Gobeaux
Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department
QJM, November 1, 2008; 101(11): 831 - 843.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. P. Goetze, U. Dahlstrom, J. F. Rehfeld, and U. Alehagen
Impact of Epitope Specificity and Precursor Maturation in Pro-B-Type Natriuretic Peptide Measurement
Clin. Chem., November 1, 2008; 54(11): 1780 - 1787.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, et al.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
Eur. Heart J., October 1, 2008; 29(19): 2388 - 2442.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, et al.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
Eur J Heart Fail, October 1, 2008; 10(10): 933 - 989.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Masson, R. Latini, I. S. Anand, S. Barlera, L. Angelici, T. Vago, G. Tognoni, J. N. Cohn, and for the Val-HeFT Investigators
Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial)
J. Am. Coll. Cardiol., September 16, 2008; 52(12): 997 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D. Kelly, S. Q. Khan, M. Thompson, G. Cockerill, L. L. Ng, N. Samani, and I. B. Squire
Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction
Eur. Heart J., September 1, 2008; 29(17): 2116 - 2124.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. Maisel, C. Mueller, K. Adams Jr., S. D. Anker, N. Aspromonte, J. G.F. Cleland, A. Cohen-Solal, U. Dahlstrom, A. DeMaria, S. Di Somma, et al.
State of the art: Using natriuretic peptide levels in clinical practice
Eur J Heart Fail, September 1, 2008; 10(9): 824 - 839.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. Y.-M. Wang and K.-N. Lai
Use of Cardiac Biomarkers in End-Stage Renal Disease
J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1643 - 1652.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. A. Fox, S. K. Shernan, C. D. Collard, K.-Y. Liu, S. F. Aranki, S. M. DeSantis, P. Jarolim, and S. C. Body
Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting.
J. Thorac. Cardiovasc. Surg., August 1, 2008; 136(2): 452 - 461.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
V. M.A. Conraads, C. De Maeyer, P. Beckers, N. Possemiers, M. Martin, V. Van Hoof, and C. J. Vrints
Exercise-induced biphasic increase in circulating NT-proBNP levels in patients with chronic heart failure
Eur J Heart Fail, August 1, 2008; 10(8): 793 - 795.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Nishii, T. Inomata, H. Takehana, T. Naruke, T. Yanagisawa, M. Moriguchi, S. Takeda, and T. Izumi
Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2329 - 2335.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. M. Mills
Learning to use a biomarker. More about B-type natriuretic peptide.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2336 - 2338.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
O. Oldenburg, A. Schmidt, B. Lamp, T. Bitter, B. G. Muntean, C. Langer, and D. Horstkotte
Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne-Stokes respiration
Eur J Heart Fail, June 1, 2008; 10(6): 581 - 586.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. Braunwald
Biomarkers in Heart Failure
N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159.
[Full Text] [PDF]

Home page
 Circ Heart FailHome page
J. J.V. McMurray, B. Pitt, R. Latini, A. P. Maggioni, S. D. Solomon, D. L. Keefe, J. Ford, A. Verma, J. Lewsey, and for the Aliskiren Observation of Heart Failure Tre
Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure
Circ Heart Fail, May 1, 2008; 1(1): 17 - 24.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
G. W Yip
B-type natriuretic peptide: a treatment, not a diagnostic marker
Heart, May 1, 2008; 94(5): 542 - 544.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
I. Squire
Assessing prognosis in heart failure: you can see a lot if you look, but more if you look again ... ... ...
Eur. Heart J., April 2, 2008; 29(8): 959 - 960.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
D. A. Pascual-Figal, M. Domingo, T. Casas, I. Gich, J. Ordonez-Llanos, P. Martinez, J. Cinca, M. Valdes, J. L. Januzzi, and A. Bayes-Genis
Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients
Eur. Heart J., April 2, 2008; 29(8): 1011 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. R. Teerlink
Learning the points of COMPASS-HF: assessing implantable hemodynamic monitoring in heart failure patients.
J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1080 - 1082.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. B. Daniels and A. S. Maisel
Natriuretic Peptides
J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2357 - 2368.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. Jourdain, G. Jondeau, and Y. Juilliere
Reply
J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2098 - 2099.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
U. C. Hoppe
Plasma Brain Natriuretic Peptide-Guided Therapy Not Yet Justified
J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2097 - 2098.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Maisel
Biomarkers in Heart Failure: Does Prognostic Utility Translate to Clinical Futility?
J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1061 - 1063.
[Full Text] [PDF]

Home page
 CirculationHome page
W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
Circulation, July 31, 2007; 116(5): e99 - e109.
[Full Text] [PDF]

Home page
 Journal Watch CardiologyHome page
B-type Natriuretic Peptide: The North Star of HF Treatment?
Journal Watch Cardiology, April 25, 2007; 2007(425): 2 - 2.
[Full Text]


 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement